

TAVI: Transcatheter Aortic Valve Implantation

REPRISE I: Transfemoral aortic valve replacement with the repositionable Lotus Valve System in high surgical risk patients: the REPRISE I study 
[links](https://eurointervention.pcronline.com/article/transfemoral-aortic-valve-replacement-with-the-repositionable-lotus-valve-system-in-high-surgical-risk-patients-the-reprise-i-study)

REPRISE II: Transcatheter Aortic Valve Replacement for Severe Symptomatic Aortic Stenosis Using a Repositionable Valve System: 30-Day Primary Endpoint Results From the REPRISE II Study
[links](https://www.jacc.org/doi/abs/10.1016/j.jacc.2014.05.067)

**REPRISE III**: Effect of Mechanically Expanded vs Self-Expanding Transcatheter Aortic Valve Replacement on Mortality and Major Adverse Clinical Events in High-Risk Patients With Aortic Stenosis: The REPRISE III Randomized Clinical Trial
[links](https://pubmed.ncbi.nlm.nih.gov/29297076/)

Two-Year Outcomes After Transcatheter Aortic Valve Replacement With Mechanical vs Self-expanding Valves
The REPRISE III Randomized Clinical Trial 
[links](https://jamanetwork.com/journals/jamacardiology/article-abstract/2725867)

Effect of Mechanically Expanded vs Self-Expanding Transcatheter Aortic Valve Replacement on Mortality and Major Adverse Clinical Events in High-Risk Patients With Aortic Stenosis
The REPRISE III Randomized Clinical Trial

Pacemaker Implantation and Dependency After Transcatheter Aortic Valve Replacement in the REPRISE III Trial
[links](https://www.ahajournals.org/doi/full/10.1161/JAHA.119.012594)

1-Year Outcomes With the Fully Repositionable and Retrievable Lotus Transcatheter Aortic Replacement Valve in 120 High-Risk Surgical Patients With Severe Aortic Stenosis: Results of the REPRISE II Study
[links](https://www.jacc.org/doi/abs/10.1016/j.jacc.2014.05.067)



